Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.
Richard LeBlancHira S MianDonna ReeceJiandong SuEsther Masih-KhanMichael ChuVictor H Jimenez-ZepedaMichael SebagKevin SongMartha LouzadaRami KotbAlissa VisramDarrell WhiteJulie StakiwAnthony ReimanMuhammad AslamDebra BergstromRayan KaedbeyEngin GulChristopher P VennerPublished in: European journal of haematology (2023)
Our observations demonstrate the poor outcome of MM patients when standard regimens based on carfilzomib and/or pomalidomide are utilized directly after daratumumab-based therapy given in the relapsed setting. Novel therapies, including immune therapies, are urgently needed to improve the outcomes of these daratumumab-exposed patients.
Keyphrases
- multiple myeloma
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- stem cells
- acute myeloid leukemia
- emergency department
- type diabetes
- metabolic syndrome
- acute lymphoblastic leukemia
- skeletal muscle
- bone marrow
- combination therapy
- diffuse large b cell lymphoma
- data analysis
- adverse drug